📊 ADVB Key Takeaways
Is Advanced Biomed Inc. (ADVB) a Good Investment?
Advanced Biomed exhibits strong profitability metrics (ROE 68.2%, ROA 59.6%) and exceptional liquidity (8.56x current ratio), but is severely constrained by negative operating cash flow of -1.1M and missing revenue data, indicating potential accounting or operational issues. The 17.1% YoY decline in net income coupled with deteriorating cash generation suggests underlying business challenges that fundamentals alone cannot fully explain.
Advanced Biomed shows an unusually strong balance sheet for its size, with high liquidity, minimal liabilities, and no leverage. However, earnings quality appears weak because reported net income is positive while operating cash flow and free cash flow are negative, and profit declined year over year. The combination suggests financial stability in the near term, but limited visibility into sustainable operating performance.
Why Buy Advanced Biomed Inc. Stock? ADVB Key Strengths
- Exceptional liquidity position with 8.56x current ratio and 2.6M cash reserves
- Very high ROE (68.2%) and ROA (59.6%) indicating efficient asset deployment
- Zero debt (0.00x Debt/Equity) with strong balance sheet structure (9.5M equity vs 1.4M liabilities)
- Positive net income of 6.5M demonstrates profitability in absolute terms
- Very strong liquidity with current and quick ratios of 8.56x
- Debt-free balance sheet with only $1.37M of liabilities against $9.48M of equity
- Positive net income and high reported ROE/ROA indicate capital-light profitability
ADVB Stock Risks: Advanced Biomed Inc. Investment Risks
- Critical red flag: Missing revenue data prevents assessment of actual business performance and margin quality
- Negative operating cash flow (-1.1M) contradicts positive net income, suggesting aggressive accounting or non-cash revenues
- Declining earnings trend with 17.1% YoY net income decline and 14.3% EPS decline indicates deteriorating business momentum
- Data quality concerns with limited available metrics and missing standard income statement components (gross profit, margins)
- Zero insider activity in past 90 days raises concerns about management confidence in company trajectory
- Negative operating cash flow and free cash flow raise concerns about earnings quality and cash conversion
- Net income declined 17.1% year over year, signaling weakening profitability
- Missing revenue and margin data reduces visibility into the durability and source of earnings
Key Metrics to Watch
- Operating cash flow recovery - critical to validate earnings quality and sustainability
- Revenue disclosure and composition - essential to understand if business is generating legitimate top-line growth
- Net income trend stabilization - monitor if 17.1% YoY decline continues or reverses
- Cash burn rate - track if negative OCF continues to erode the 2.6M cash position
- Operating cash flow relative to net income
- Revenue growth and operating margin consistency
Advanced Biomed Inc. (ADVB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.56x current ratio provides a solid financial cushion.
ADVB Profit Margin, ROE & Profitability Analysis
ADVB vs Healthcare Sector: How Advanced Biomed Inc. Compares
How Advanced Biomed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Advanced Biomed Inc. Stock Overvalued? ADVB Valuation Analysis 2026
Based on fundamental analysis, Advanced Biomed Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Advanced Biomed Inc. Balance Sheet: ADVB Debt, Cash & Liquidity
ADVB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Advanced Biomed Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.14 indicates the company is currently unprofitable.
ADVB Revenue Growth, EPS Growth & YoY Performance
Advanced Biomed Inc. Dividends, Buybacks & Capital Allocation
ADVB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Advanced Biomed Inc. (CIK: 0001941029)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADVB
What is the AI rating for ADVB?
Advanced Biomed Inc. (ADVB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADVB's key strengths?
Claude: Exceptional liquidity position with 8.56x current ratio and 2.6M cash reserves. Very high ROE (68.2%) and ROA (59.6%) indicating efficient asset deployment. ChatGPT: Very strong liquidity with current and quick ratios of 8.56x. Debt-free balance sheet with only $1.37M of liabilities against $9.48M of equity.
What are the risks of investing in ADVB?
Claude: Critical red flag: Missing revenue data prevents assessment of actual business performance and margin quality. Negative operating cash flow (-1.1M) contradicts positive net income, suggesting aggressive accounting or non-cash revenues. ChatGPT: Negative operating cash flow and free cash flow raise concerns about earnings quality and cash conversion. Net income declined 17.1% year over year, signaling weakening profitability.
What is ADVB's revenue and growth?
Advanced Biomed Inc. reported revenue of N/A.
Does ADVB pay dividends?
Advanced Biomed Inc. does not currently pay dividends.
Where can I find ADVB SEC filings?
Official SEC filings for Advanced Biomed Inc. (CIK: 0001941029) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADVB's EPS?
Advanced Biomed Inc. has a diluted EPS of $0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADVB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Advanced Biomed Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ADVB stock overvalued or undervalued?
Valuation metrics for ADVB: ROE of 68.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ADVB stock in 2026?
Our dual AI analysis gives Advanced Biomed Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADVB's free cash flow?
Advanced Biomed Inc.'s operating cash flow is $-1.1M, with capital expenditures of $14.7K.
How does ADVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE 68.2% (avg: 15%), current ratio 8.56 (avg: 2).
Why is ADVB's return on equity (ROE) so high?
Advanced Biomed Inc. has a return on equity of 68.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity.